Results 141 to 150 of about 164,933 (217)

A semi-automated quality assurance tool for cardiovascular magnetic resonance imaging: application to outlier detection, artificial intelligence evaluation and trainee feedback. [PDF]

BMC Med Inform Decis Mak
Hadler T, Grassow L, Kuhnt J, Hickstein R, Saad H, Fenski M, Gröschel J, Trauzeddel RF, Blaszczyk E, Ammann C, Viezzer D, Hennemuth A, Lange S, Schulz-Menger J.   +13 more
europepmc   +1 more source

Review of the Current State of Artificial Intelligence in Pediatric Cardiovascular Magnetic Resonance Imaging. [PDF]

Children (Basel)
Gearhart A, Anjewierden S, Buddhe S, Tandon A.   +3 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Inter-technique agreement of left atrial and ventricular deformation analysis: a comparison between transthoracic echocardiography and cardiovascular magnetic resonance imaging. [PDF]

Echo Res Pract
Alfuhied A, Yeo JL, Gulsin GS, Dattani A, Parke K, Steadman CD, Sian M, Marsh AM, McCann GP, Singh A.   +9 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Cardiovascular magnetic resonance imaging markers of ageing: a multi-centre, cross-sectional cohort study. [PDF]

Eur Heart J Open
Assadi HS, Zhao X, Matthews G, Li R, Broncano Cabrero J, Kasmai B, Alabed S, Royuela Del Val J, Spohr H, Gurung-Koney Y, Aung N, Nair S, Swift AJ, Vassiliou VS, Zhong L, Al-Mohammad A, van der Geest RJ, Swoboda PP, Plein S, Garg P.   +19 more
europepmc   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging. [PDF]

Heart
Dobbin SJH, Mangion K, Berry C, Roditi G, Basak S, McClure JD, Brooksbank K, Sonecki P, Sourbron S, Evans J, White J, Welsh P, Butler E, Venugopal B, Touyz RM, Jones RJ, Petrie MC, Lang NN.   +17 more
europepmc   +1 more source

Fetal and Infant Growth and the Cardiovascular Stress Response in Adolescence: A Cardiovascular Magnetic Resonance Imaging Study in a Pediatric Population-Based Cohort. [PDF]

J Am Heart Assoc
Kamphuis ASJ, Hirsch A, Rizopoulos D, Budde RPJ, Roest AAW, Jaddoe VWV, Gaillard R.   +6 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source